Predictors of Cardiovascular Symptoms Among Long COVID Patients: Data from the Polish Long COVID Cardiovascular (PoLoCOV-CVD) Study.

Publication date: Feb 02, 2025

Background and aims: Long COVID symptoms persist globally, with a notable rise in cardiovascular disease (CVD) among COVID-19 survivors, including those without prior risk factors or hospitalizations. This study aims to identify predictors of cardiovascular-related Long COVID symptoms. Methods: This study included subjects with post-SARS-CoV-2 infections, categorizing them into three groups: non-Long COVID (non-LC), Long COVID (LC), and Long COVID with cardiovascular symptoms (cardio-LC) as part of the Polish Long COVID Cardiovascular (PoLoCOV-CVD) study collected between the years 2020 and 2022, comprising 4000 participants. Chi-square tests and logistic regression were used to report the prevalence and determinants of quality of life in cardio-LC, based on patient self-reported data including comorbidities and medications. Results: Of the 704 patients analyzed, 71. 9% were female with a median age of 54 years (IQR: 45-64). Cardio-LC patients had statistically significant differences relative to the non-LC group in terms of blood pressure, elevated LDL cholesterol (p = 0. 010), and non-HDL cholesterol (p = 0. 013). In addition, cardio-LC patients were more likely to be female (p < 0. 001) who exhibited psychological conditions, such as sleep disturbances (p < 0. 001), anxiety (p < 0. 001), and depression (p < 0. 001) compared to the non-LC group. However, the multivariable logistic regression analysis revealed that only the female gender and sleep disturbances remained an independent predictor associated with cardio-LC (OR: 1. 66, CI 1. 12-2. 46; OR: 1. 742, CI 1. 12-2. 70) compared to participants without Long COVID. Conclusions: The significant positive association of female gender and sleep disturbances with cardiovascular complications during Long COVID highlights critical demographic and psychological factors that deserve attention in clinical practice.

Open Access PDF

Concepts Keywords
Cholesterol cardiovascular disease
Covid COVID-19
Globally long COVID
Hospitalizations non-hospitalized
predictors
SARS-CoV-2

Semantics

Type Source Name
disease MESH Long COVID
disease MESH cardiovascular disease
disease MESH COVID-19
disease IDO quality
disease IDO blood
disease MESH anxiety
disease MESH depression
disease MESH complications
drug DRUGBANK Coenzyme M
disease MESH Hypertension
disease MESH infections
disease MESH pneumonia
disease MESH hypoxia
disease MESH interstitial pneumonia
disease MESH syndrome
disease MESH glucose intolerance
disease MESH tachycardia
disease MESH cardiovascular risk
disease MESH cerebrovascular disorders
disease MESH heart disease
disease MESH ischemic heart disease
disease MESH heart failure
disease MESH obesity
disease MESH chronic kidney disease
disease MESH lipidemia
drug DRUGBANK Methionine
disease MESH anemia
disease MESH hyperthyroidism
disease MESH hypothyroidism
disease IDO history
disease MESH cancer
disease MESH sweating
disease MESH hair loss
disease MESH anosmia
disease MESH ageusia
disease MESH conjunctivitis
disease MESH arthralgia
disease MESH dyspnea
disease MESH syncope
disease MESH chest pain
drug DRUGBANK Dextromethorphan
drug DRUGBANK Cholesterol
drug DRUGBANK Dextrose unspecified form
disease MESH Insulin Resistance
pathway KEGG Insulin resistance
disease MESH venous thromboembolism
disease MESH asthma
pathway KEGG Asthma
disease MESH pulmonary disease
disease MESH thyroid disease
drug DRUGBANK Calcium
disease MESH COPD
disease MESH thromboembolism
disease MESH comorbidity

Original Article

(Visited 1 times, 1 visits today)